Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients (MARINA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05027269 |
Recruitment Status :
Completed
First Posted : August 30, 2021
Last Update Posted : February 5, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients (MARINA).
Part A is a single dose design with 1 cohort (dose level). In Part A, the patient duration is 6 months as the treatment period is 1 day followed by a 6 month follow-up period.
Part B is a multiple-ascending dose design with 2 cohorts (dose levels). In Part B, the patient duration is 6 months as the treatment period is 3 months followed by a 3 month follow-up period.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
DM1 Myotonic Dystrophy 1 Myotonic Dystrophy Myotonic Dystrophy Type 1 (DM1) Dystrophy Myotonic Myotonic Disorders Steinert Disease Myotonic Muscular Dystrophy | Drug: AOC 1001 Drug: Placebo | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 38 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients |
Actual Study Start Date : | October 28, 2021 |
Actual Primary Completion Date : | February 14, 2023 |
Actual Study Completion Date : | February 14, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A Single Dose: AOC 1001 Dose Level 1
AOC 1001 will be administered once.
|
Drug: AOC 1001
AOC 1001 will be administered by intravenous (IV) infusion. |
Placebo Comparator: Part A Single Dose: Placebo
Saline will be administered once.
|
Drug: Placebo
Placebo will be administered by intravenous (IV) infusion. |
Experimental: Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2 & 3
AOC 1001 will be administered three times.
|
Drug: AOC 1001
AOC 1001 will be administered by intravenous (IV) infusion. |
Placebo Comparator: Part B Multiple Ascending Dose: Placebo
Saline will be administered three times.
|
Drug: Placebo
Placebo will be administered by intravenous (IV) infusion. |
- Frequency of treatment emergent adverse events (TEAEs) [ Time Frame: Through study completion, up to Day 183 ]
- Plasma pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]Maximum plasma concentration (Cmax)
- Plasma pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]Time to maximum plasma concentration (Tmax)
- Plasma pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]Terminal Half-life (t1/2)
- Plasma pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]Area Under the Concentration-time Curve (AUC)
- Urine pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]fraction excreted (fe) in urine
- AOC 1001 levels in muscle tissue [ Time Frame: Through study completion, up to Day 183 ]
- Change and percentage change from baseline in DMPK mRNA knockdown [ Time Frame: Through study completion, up to Day 183 ]
- Change and percentage change from baseline in Spliceopathy [ Time Frame: Through study completion, up to Day 183 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Genetic diagnosis of DM1 (CTG repeat length ≥ 100)
- Clinician assessed signs of DM1
- Ability to walk independently (orthoses and ankle braces allowed) for at least 10 meters at screening
Key Exclusion Criteria:
- Diabetes that is not adequately controlled
- BMI > 35 kg/m2
- Uncontrolled hypertension
- Congenital DM1
- History of tibialis anterior (TA) biopsy within 3 months of Day 1 or planning to undergo TA biopsies during study period
- Recently treated with an investigational drug
- Treatment with anti-myotonic medication within 14 days of Day 1
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05027269
United States, California | |
University of California Los Angeles | |
Los Angeles, California, United States, 90095 | |
Stanford University | |
Palo Alto, California, United States, 94304 | |
United States, Colorado | |
University of Colorado | |
Denver, Colorado, United States, 80045 | |
United States, Florida | |
University of Florida | |
Gainesville, Florida, United States, 32608 | |
United States, Kansas | |
Kansas University Medical Center | |
Kansas City, Kansas, United States, 66205 | |
United States, New York | |
University of Rochester Medical Center | |
Rochester, New York, United States, 14642 | |
United States, Ohio | |
Ohio State University | |
Columbus, Ohio, United States, 43221 | |
United States, Virginia | |
Virginia Commonwealth University | |
Richmond, Virginia, United States, 23298 |
Study Director: | Li Tai, MD | Avidity Biosciences, Inc. |
Responsible Party: | Avidity Biosciences, Inc. |
ClinicalTrials.gov Identifier: | NCT05027269 |
Other Study ID Numbers: |
AOC 1001-CS1 |
First Posted: | August 30, 2021 Key Record Dates |
Last Update Posted: | February 5, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
DM1 Myotonic Dystrophy 1 Myotonic Dystrophy Type 1 (DM1) Myotonic Dystrophy DM Dystrophy Myotonic Myotonic Disorders |
Steinert Disease MARINA Avidity Biosciences Avidity AOC 1001 Myotonic Muscular Dystrophy |
Muscular Dystrophies Myotonic Dystrophy Myotonic Disorders Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases |
Neuromuscular Diseases Nervous System Diseases Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases |